These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7214106)

  • 41. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
    Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined treatment of schizophrenic psychoses with haloperidol and valproate.
    Dose M; Hellweg R; Yassouridis A; Theison M; Emrich HM
    Pharmacopsychiatry; 1998 Jul; 31(4):122-5. PubMed ID: 9754845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels.
    Altamura CA; Colacurcio F; Mauri MC; Moro AR; De Novellis F
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):25-35. PubMed ID: 1967847
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum prolactin and clinical state during neuroleptic treatment and withdrawal.
    Laughren TP; Brown WA; Williams BW
    Am J Psychiatry; 1979 Jan; 136(1):108-10. PubMed ID: 758812
    [No Abstract]   [Full Text] [Related]  

  • 48. The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.
    Allan ER; Sison CE; Alpert M; Connolly B; Crichton J
    Psychopharmacol Bull; 1998; 34(1):71-4. PubMed ID: 9564201
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 50. [Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
    Potanin SS; Burminskiy DS; Morozova MA; Platova AI; Baymeeva NV; Miroshnichenko II
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):40-46. PubMed ID: 26978050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin.
    Kondo T; Ishida M; Tokinaga N; Mihara K; Yasui-Furukori N; Ono S; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Feb; 26(2):287-91. PubMed ID: 11817505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. RBC and plasma levels of haloperidol and clinical response in schizophrenia.
    Smith RC; Vroulis G; Shvartsburd A; Allen R; Lewis N; Schoolar JC; Chojnacki M; Johnson R
    Am J Psychiatry; 1982 Aug; 139(8):1054-6. PubMed ID: 7091432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of extrapyramidal side effects of haloperidol through the joint use of imipramine-type drugs.
    Butterworth AT
    Psychosomatics; 1972; 13(5):328-32. PubMed ID: 4671924
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of haloperidol on aldosterone secretion.
    Warner MD; Gillespie H; Pavlou SN; Nader S; Peabody CA
    Psychoneuroendocrinology; 1992 Oct; 17(5):517-21. PubMed ID: 1484918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Haloperidol plasma levels and clinical response in paranoid schizophrenics.
    Linkowski P; Hubain P; von Frenckell R; Mendlewicz J
    Eur Arch Psychiatry Neurol Sci; 1984; 234(4):231-6. PubMed ID: 6526061
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A crossover study of clocapramine and haloperidol in chronic schizophrenia.
    Yamagami S
    J Int Med Res; 1985; 13(6):301-10. PubMed ID: 4076529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 59. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study.
    Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
    Psychopharmacology (Berl); 2005 Feb; 178(1):35-40. PubMed ID: 15289996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolactin response to bromperidol treatment in schizophrenic patients.
    Yasui N; Kondo T; Otani K; Ishida M; Mihara K; Suzuki A; Kaneko S; Inoue Y
    Pharmacol Toxicol; 1998 Mar; 82(3):153-6. PubMed ID: 9553995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.